“Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer”: is there a substantial difference or not?

Metastatic non-small cell lung cancer (NSCLC) is still an incurable disease, despite the significant improvement in prognostic outcomes [progression-free survival (PFS) and overall survival (OS)] which has been seen in recent years following the advent of immunomodulatory drugs aimed at inhibiting immune checkpoints.